CJC-1295 with DAC
Also known as: CJC-1295 DAC, Drug Affinity Complex
Molecular Identifiers
Molecular Formula
C165H269N47O46
CAS Number
863288-34-0
PubChem CID
91971820Molecular Weight
3647.28 Da
Overview
Long-acting GH secretagogue. Provides sustained GH elevation through albumin conjugation (DAC), extending the half-life to 6-8 days. Frequently combined with Ipamorelin for synergistic effect.
The main appeal of CJC-1295 with DAC is practicality combined with sustained GH and IGF-1 elevation: by binding to serum albumin via the Drug Affinity Complex, its half-life extends to 6-8 days, allowing one weekly injection instead of multiple daily applications. It is sought for body recomposition, sleep quality, tissue recovery, and hormonal optimization in adults.
It has no approval as a medicine by the FDA, EMA, or ANVISA. In Brazil it is prescribed by compounding pharmacies as off-label use, usually in 8 to 12-week cycles, often combined with Ipamorelin to combine an acute pulse (GHRP) with tonic elevation (GHRH analog). WADA lists GHRH and analogs as substances prohibited in sport.
It was developed by ConjuChem as a modified GHRH(1-29) analog with a maleimido linker that conjugates in vivo to albumin. Unlike CJC-1295 without DAC (Mod GRF 1-29), it produces a prolonged GH plateau rather than physiological pulses, which increases side effects related to water retention and tingling.
Across the GH secretagogue landscape, CJC-1295 with DAC is the longest-acting GHRH analog: while sermorelin and Mod GRF 1-29 require multiple daily injections and tesamorelin is dosed once daily, the DAC version allows weekly injection — at the cost of losing the physiological pulsatile pattern. For that reason it is typically combined with a GHRP such as ipamorelin, GHRP-2, or hexarelin, or contrasted with oral MK-677 when convenience is the priority.
YADAIFTQSYRKVLAQLSARKLLQDILSR Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg Half-life
~6-8 days
Administration Route
Subcutaneous
Category
GH Secretagogues
Mechanism of Action
- GHRH receptor agonist in the anterior pituitary
- Albumin conjugation via Drug Affinity Complex extends half-life
- Sustained stimulation of GH secretion for 6-8 days
- Elevation of serum IGF-1
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 1-2 mg per week |
| Frequency | Once per week |
| Timing | Before bedtime |
| Duration | 8-12 weeks minimum |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Facial flushing
- Water retention
- Tingling
- Headache
- Drowsiness
Product Properties
| Purity | >99% |
| Appearance | White lyophilized powder |
| Solubility | Soluble in water and bacteriostatic water |
| Source | Solid-phase peptide synthesis (SPPS) |
| Storage | Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C for up to 4 weeks. Protect from light and moisture. Avoid repeated freeze-thaw cycles. |
Presentations & Preparation
Vials of CJC-1295 with DAC found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per 5 mg vial
- Inject the diluent slowly against the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: Room temperature or -20°C (up to 24 months)
- Reconstituted: Refrigerated 2-8°C (up to 30 days)
- Protect from direct light
- Do not freeze after reconstitution
Scientific Studies
Published studies on CJC-1295 with DAC.
Safety and tolerability of long-acting release recombinant human growth hormone-releasing hormone in adults with growth hormone deficiency
Ionescu M, Frohman LA
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA
Related Peptides
CJC-1295 sem DAC
100-200 mcg per injection · 2-3 times daily
GHRP-2
100-300 mcg per injection · 2-3 times per day
GHRP-6
100-300 mcg per injection · 2-3 times per day
Hexarelin
200-300 mcg per injection · 2-3 times per day
Ipamorelin
200-300 mcg per injection · 2-3 times daily
MK-677
10-25 mg per dose · Once daily